A case of Behçet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab

Modern Rheumatology

Volumn 22, Issue 2, 2012, Pages 298-302

  Hirano, Toru ^a   Ohguro, Nobuyuki ^b   Hohki, Satoshi ^c   Hagihara, Keisuke ^a   Shima, Yoshihito ^a   Narazaki, Masashi ^a   Ogata, Atsushi ^a   Yoshizaki, Kazuyuki ^d   Kumanogoh, Atsushi ^a   Kishimoto, Tadamitsu ^d   Tanaka, Toshio ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA KOSEI NENKIN HOSPITAL   (Japan)

^c UNIVERSITY OF TOYAMA   (Japan)

^d OSAKA UNIVERSITY   (Japan)

Author keywords

Beh et's disease; IL 6; Tocilizumab

Indexed keywords

COLCHICINE; CYCLOSPORIN A; INFLIXIMAB; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PREDNISOLONE; TOCILIZUMAB; TRIAMCINOLONE;

ADD ON THERAPY; ADULT; ARTICLE; BEHCET DISEASE; CASE REPORT; CLINICAL FEATURE; DETERIORATION; DRUG EFFECT; ERYTHEMA NODOSUM; FEMALE; GENITAL ULCER; HUMAN; MONOTHERAPY; MOUTH ULCER; PRIORITY JOURNAL; QUALITY OF LIFE; RELAPSE; REMISSION; TREATMENT RESPONSE; UVEITIS; VISUAL ACUITY;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BEHCET SYNDROME; COLCHICINE; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOLOGIC FACTORS; MIDDLE AGED; PREDNISOLONE; RECEPTORS, INTERLEUKIN-6; REMISSION INDUCTION; TREATMENT FAILURE;

EID: 84861483650     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-011-0497-5     Document Type: Article

References (24)

1. Mendes D, Correia M, Barbedo M, Vaio T, Mota M. Behçet's disease - a contemporary review. J Autoimmun. 2009;32:178-88.
2. Fresko I, Yazici H. Treatment strategies for Behçet's disease. Expert Opin Pharmacother. 2008;9:3211-9.
3. Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, et al. EULAR recommendations for the management of Behçet disease. Ann Rheum Dis. 2008;67:1656-62.
4. Ohno S, Nakamura S, Hori S, Shimakawa M, Kawashima H, Mochizuki M, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis. J Rheumatol. 2004;31:1362-8. (Pubitemid 38879203)
5. Remmers EF, Cosan F, Kirino Y, Ombrello MJ, Abaci N, Satorius C, et al. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R/IL12RB2 regions associated with Behçet's disease. Nat Genet. 2010;42:698-702.
6. Mizuki N, Meguro A, Ota M, Ohno S, Shiota T, Kawagoe T, et al. Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behçet's disease susceptibility loci. Nat Genet. 2010;42:703-6.
7. Hamzaoui K, Hamzaoui A, Guemira F, Bessioud M, Hamza M, Ayed K. Cytokine profile in Behçet's disease patients. Relationship with disease activity. Scand J Rheumatol. 2002; 31:205-10. (Pubitemid 34971876)
8. Hirohata S, Oka H, Mizushima Y. Streptococcal-related antigens stimulate production of IL6 and interferon-gamma by T cells from patients with Behçet's disease. Cell Immunol. 1992; 140:410-9.
9. Mege JL, Dilsen N, Sanguedolce V, Gul A, Bongrand P, Roux H, et al. Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behçet's disease. A comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol. 1993;20:1544-9. (Pubitemid 24027329)
10. Wang CR, Chuang CY, Chen CY. Anticardiolipin antibodies and interleukin-6 in cerebrospinal fluid and blood of Chinese patients with neuro-Behçet's syndrome. Clin Exp Rheumatol. 1992; 10:599-602.
11. Hirohata S, Isshi K, Oguchi H, Ohse T, Haraoka H, Takeuchi A, et al. Cerebrospinal fluid interleukin-6 in progressive neuro-Behc ̧et's syndrome. Clin Immunol Immunopathol. 1997;82:12-7. (Pubitemid 27049067)
12. Tanaka T, Ogata A, Narazaki M. Tocilizumab for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol. 2010; 6:843-54.
13. The classification criteria for Behçet's disease. Japanese Ministry of Health and Welfare. 1987.
14. Bhakta BB, Brennan P, James TE, Chamberlain MA, Noble BA, Silman AJ. Behçet's disease: evaluation of a new instrument to measure clinical activity. Rheumatology. 1999;38:728-33. (Pubitemid 29507389)
15. Fukuhara S, Bito S, Green J, Hsiao A, Kurokawa K. Translation, adaptation, and validation of the SF-36 Health Survey for use in Japan. J Clin Epidemiol. 1998;51:1037-44. (Pubitemid 28527159)
16. Sfikakis N, Markomichelakis N, Alpsoy E, Assaad-Khalil S, Bodaghi B, Gul A, et al. Anti-TNF therapy in the management of Behçet's disease - review and basis for recommendations. Rheumatology. 2007;46:736-41. (Pubitemid 47061701)
17. Kotter I, Zierhut M, Eckstein AK, Vonthein R, Ness T, Gunaydin I, et al. Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis. Br J Ophthalmol. 2003;87:423-31. (Pubitemid 36399030)
18. Ohguro N, Yamanaka E, Otori Y, Saishin Y, Tano Y. Repeated intravitreal triamcinolone injections in Behçet's disease that is resistant to conventional therapy: one-year results. Am J Ophthalmol. 2006;141:218-20. (Pubitemid 43016208)
19. Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 2008; 112:3959-64.
20. Tanaka T, Narazaki M, Kishimoto T. Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases. FEBS Lett (in press).
21. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, et al. Reciprocal developmental pathways for the generation of pathogenic effector Th17 and regulatory T cells. Nature. 2006; 441:235-8.
22. Yoshimura T, Sonoda K, Ohguro N, Ohsugi Y, Ishibashi T, Cua DJ, et al. Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis. Rheumatology. 2009;48:347-54.
23. Hohki S, Ohguro N, Haruta H, Nakai K, Terabe F, Serada S, et al. Blockade of interleukin-6 signaling suppresses experimental autoimmune uveoretinitis by the inhibition of inflammatory Th17 responses. Exp Eye Res. 2010;91:162-70.
24. Haruta H, Ohguro N, Fujimoto M, Hohki S, Terabe F, Serada S, et al. Blockade of interleukin-6 signaling suppresses not only Th17 but also interphotoreceptor retinoid binding protein-specific Th1 by promoting regulatory T cells in experimental autoimmune uveoretinitis. Invest Opthalmol Vis Sci. 2011;52:3264-71.